12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Elan, Royalty Pharma deal

Elan said its board unanimously rejected an unsolicited tender offer from Royalty Pharma to acquire the biotech for $11.25 per share, which values the biotech at $5.7 billion. Elan said the offer "grossly undervalues" the company's current business platform and...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >